Through the CAHmelia trials. Spruce Biosciences is evaluating once-daily tildacerfont, a new investigational drug that seeks to shift the treatment paradigm for congenital adrenal hyperplasia (CAH). Tildacerfont is NOT a steroid. The primary purpose of the CAHmelia program is to assess if tildacerfont is effective in lowering androgens (testosterone related hormones) and daily glucocorticoid doses in patients with classic CAH.
For more information on the ongoing trials in adult patients with classic CAH, please visit: